RedHill Biopharma Ltd. business relationships
Companies named in RedHill Biopharma Ltd.’s 20-F filed 2026-04-27, and public companies whose annual reports name RedHill Biopharma Ltd.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.5 / 10
- AI naming
- <1 / 100 Top 55% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in RedHill Biopharma Ltd.’s annual report 8
“Effective April 1, 2020 (the ("Effective Date"), RedHill Inc. entered into an exclusive license agreement with AstraZeneca, granting RedHill Inc. exclusive, worldwide (excluding Europe, Canada) commercialization and development rights to Movantik ® (naloxegol).” SEC filing
“The research and development of certain of our product candidates, including opaganib, are supported by grants and industry partners (e.g. ANZUP/Bayer)” SEC filing
“We require any active third-party supplier to work with Single Sign On in our system, using our identity provider, all except the financial SAP system in which we separate from information technology by design.” SEC filing
“| | ● | | the ability to successfully commercialize Talicia ® in the U.S as part of our collaboration arrangement with Cumberland Pharmaceuticals Inc. ("Cumberland") and successfully implement joint decision-making and division of responsibilities for such collaboration; |” SEC filing
“...ortfolio protecting the new chemical entity (WX-UK1), the pro-drug ("WX-671" or "RHB-107" or "upamostat"), formulations comprising upamostat, methods of synthesizing the compounds, and methods of using upamostat to treat cancer, was in-licensed by us from Wilex AG, now known as Heidelberg Pharma AG.” SEC filing
“| | ● | | our partners, such as Hyloris and Cumberland, may not pursue their activities under our license agreements, or may not be able to develop, manufacture, register and/or commercialize our products, directly or through third parties, distributors and/or sublicensees. |” SEC filing
“| | ● | | our partners, such as Hyloris and Cumberland, may not pursue their activities under our license agreements, or may not be able to develop, manufacture, register and/or commercialize our products, directly or through third parties, distributors and/or sublicensees. |” SEC filing
“Our intellectual property rights to opaganib, which we in-licensed from Apogee Biotechnology Corporation, have been generated through the use of U.S. federal and state government funding and are therefore subject to certain federal regulations.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.